课题基金 / 基金详情

项目摘要

项目成果

Nancy Maizels的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
 DESCRIPTION (provided by applicant): Some very potent chemotherapeutics used in the clinic function by stabilizing covalent protein-DNA adducts formed as obligatory intermediates in normal cellular function. Despite the demonstrated effectiveness of these drugs, there has been no effort to systematically identify all targets of drugs in this class. Our proposal describes a novel approach that combines stringent enrichment of covalent protein adducts upon drug treatment with unbiased proteomics to identify and discover drug targets. Using this approach, we have confirmed known targets of topotecan and etoposide, and we have identified novel targets of these drugs, thereby establishing the power of this approach as a discovery tool. We propose to apply this approach to identify the targets of six chemotherapeutic drugs that function by this mechanism: etoposide, doxorubicin, topotecan, decitabine (5-aza-dC), azacitidine (5-aza-C) and olaparib, and to validate these targets. Success in these experiments will identify new targets of drugs in current use, and establish a general approach for determining mechanisms of drug action to enable future identification of novel drug-target pairs.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Mechanism-based targeting of bacterial topoisomerases
  • 批准号:
    9243114
  • 项目类别:
  • 资助金额:
    $21.5万
  • 财政年份:
    2016
  • 负责人:
    Nancy Maizels
  • 依托单位:
Novel Targets of Chemotherapeutic Drugs that Trap Protein on DNA
  • 批准号:
    9031087
  • 项目类别:
  • 资助金额:
    $20.16万
  • 财政年份:
    2015
  • 负责人:
    Nancy Maizels
  • 依托单位:
Mechanisms of loss of heterozygosity in cancer
  • 批准号:
    8989522
  • 项目类别:
  • 资助金额:
    $20.16万
  • 财政年份:
    2014
  • 负责人:
    Nancy Maizels
  • 依托单位:
Mechanisms of loss of heterozygosity in cancer
  • 批准号:
    8805324
  • 项目类别:
  • 资助金额:
    $16.8万
  • 财政年份:
    2014
  • 负责人:
    Nancy Maizels
  • 依托单位:
国内基金
海外基金
CRISPR/Cas9全基因组文库筛选Venetoclax/Azacitidine耐药关键基因及其机制研究